Roche Holdings Ltd ADR (RHHBY)

$41.85 -0.63 (-1.48%)
Market Cap 270.25B
Revenue (ttm) 70.87B
Net Income (ttm) 9.40B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 14.77
Profit Margin 13.27%
Debt to Equity Ratio 0.96
Volume 2,084,300
Avg Vol 1,363,180
Day's Range N/A - N/A
Shares Out 6.36B
Stochastic %K 77%
Beta 0.47
Analysts Hold
Price Target $43.38

Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19,...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 41 61 688 88 80
Fax: 41 61 691 00 14
Address:
Grenzacherstrasse 124, Basel, Switzerland
Quantumup
Quantumup Sep. 10 at 12:37 PM
Oppenheimer⬆️the PT on $TYRA to $36 from $30 reiterated at an Outperform and said, we hosted $TYRA for meetings in Boston on Monday. [ $REGN $PFE $RHHBY $MRK BMY ] In each meeting, management made the case for why dabogratinib's combined market opportunity exceeds $10B. That's nearly Regeneron-esque revenues. Despite that, investors still complain that all the major catalysts aren't until 2026. Fine. But don't expect to find shares at this price -with a sub-$500M enterprise value-next year. This is one of the most de-risked stories we've ever covered because the roles that FGFR3 plays in both cancer and bone growth are so well-validated. What we hadn't truly appreciated was the sheer size of the market. We are revamping our model to increase peak sales in both NMIBC and Achondroplasia, while still feeling that our numbers leave room for upside. Reiterate Outperform; PT to $36.
0 · Reply
DonCorleone77
DonCorleone77 Sep. 9 at 11:13 PM
$AZN $GSK $NVS $RHHBY $BMY President Trump signed a memorandum mandating that pharmaceutical advertisements increase the amount of information regarding risks of the drug in question.
0 · Reply
LVCENTVM
LVCENTVM Sep. 9 at 5:11 PM
Altai Capital and the Hypothesis Behind OraSure and ContextLogic’s Hidden value $LOGC $OSUR $RHHBY https://medium.com/@federico.rodenas/altai-capital-and-the-hypothesis-behind-orasure-and-contextlogics-hidden-value-ea2ab379be46
0 · Reply
dogDazeSummer
dogDazeSummer Sep. 9 at 1:06 PM
$IFRX HCW- Con’t CSU: “CSU represents a significant commercial opportunity. In the U.S., urticaria prevalence is estimated to be 0.5-1% of the total population (approximately 1 to 3 million individuals). Estimates place the CSU market value at approximately $2 billion in the U.S., and a $7-8 billion market for the indication worldwide. Unfortunately, available therapies are limited and only provide symptomatic relief. Current options include: 1) antihistamines, 2) leukotriene receptor antagonists, 3) omalizumab (brand name XOLAIR), $RHHBY 4) dupilumab (brand name DUPIXENT) $SNY and $REGN https://www.barrons.com/articles/regeneron-blockbuster-dupixent-rival-ef230b36
0 · Reply
Gromit00
Gromit00 Sep. 8 at 4:45 PM
$LCTX Dear $RHHBY, Lineage just got a whole lot more expensive.
0 · Reply
Quantumup
Quantumup Sep. 8 at 10:25 AM
Citizens⬆️ $IDYA's PT to $45 from $41, reiterated at a Market Outperform and said, IDEAYA Biosciences's partner Hengrui showed strong numbers with DLL3-ADC IDE849 (SHR4849) in updated Ph1 data in Chinese patients that cleared the hurdle with more room than anticipated. $AZN $RHHBY $BMY $ZLAB ABBV Citizens added, IDE849 checked all the boxes and showed best-in-class efficacy as well as duration compared to the competitive landscape (details inside). We point to $IDYA's R&D day on Monday morning for more details and we expect the stock to react positively (+10%) on this strong update. We maintain our Market Outperform rating and increase our DCF-derived price target to $45 from $41 based on an increased probability of success (25% from 15%) for IDE849.
0 · Reply
Fingerlickengood
Fingerlickengood Sep. 7 at 6:54 PM
$CDXS $ALNY $RHHBY https://www.biotechtv.com/post/corsera-health-john-maraganore
3 · Reply
Fingerlickengood
Fingerlickengood Sep. 7 at 6:48 PM
$CDXS $ALNY $RHHBY This statement from the attached article stands out to me regarding Corsera Health, "With a preventive RNAi medicine expected to enter the clinic by the end of 2025, administered once-annually and priced to enable broad access, Corsera Health aims to prevent cumulative cardiovascular damage and support longer, healthier lives." This suggests they possibly have acquired something nearing or already FDA approved. What exactly is that is yet to be seen! https://www.streetinsider.com/dr/news.php?id=25280745
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Sep. 7 at 2:15 AM
$LMDX $RHHBY I get your frustration. A lot of us feel burned. The truth is, there’s a lot more to this story than just a ‘dead stock.’ Some of the most valuable assets — like the TB test and other pipeline IP — were never properly accounted for in the Roche deal. Insiders made out okay, but regular shareholders didn’t. You’re not wrong to feel scammed.
1 · Reply
DmcMouse
DmcMouse Sep. 5 at 8:38 PM
$LMDX what is everyone hearing anything good? Come one $RHHBY pay us our shares. Your gonna make enough take care of us little guys for once! Do the right thing.......$RHHBY
1 · Reply
Latest News on RHHBY
No data available.
Quantumup
Quantumup Sep. 10 at 12:37 PM
Oppenheimer⬆️the PT on $TYRA to $36 from $30 reiterated at an Outperform and said, we hosted $TYRA for meetings in Boston on Monday. [ $REGN $PFE $RHHBY $MRK BMY ] In each meeting, management made the case for why dabogratinib's combined market opportunity exceeds $10B. That's nearly Regeneron-esque revenues. Despite that, investors still complain that all the major catalysts aren't until 2026. Fine. But don't expect to find shares at this price -with a sub-$500M enterprise value-next year. This is one of the most de-risked stories we've ever covered because the roles that FGFR3 plays in both cancer and bone growth are so well-validated. What we hadn't truly appreciated was the sheer size of the market. We are revamping our model to increase peak sales in both NMIBC and Achondroplasia, while still feeling that our numbers leave room for upside. Reiterate Outperform; PT to $36.
0 · Reply
DonCorleone77
DonCorleone77 Sep. 9 at 11:13 PM
$AZN $GSK $NVS $RHHBY $BMY President Trump signed a memorandum mandating that pharmaceutical advertisements increase the amount of information regarding risks of the drug in question.
0 · Reply
LVCENTVM
LVCENTVM Sep. 9 at 5:11 PM
Altai Capital and the Hypothesis Behind OraSure and ContextLogic’s Hidden value $LOGC $OSUR $RHHBY https://medium.com/@federico.rodenas/altai-capital-and-the-hypothesis-behind-orasure-and-contextlogics-hidden-value-ea2ab379be46
0 · Reply
dogDazeSummer
dogDazeSummer Sep. 9 at 1:06 PM
$IFRX HCW- Con’t CSU: “CSU represents a significant commercial opportunity. In the U.S., urticaria prevalence is estimated to be 0.5-1% of the total population (approximately 1 to 3 million individuals). Estimates place the CSU market value at approximately $2 billion in the U.S., and a $7-8 billion market for the indication worldwide. Unfortunately, available therapies are limited and only provide symptomatic relief. Current options include: 1) antihistamines, 2) leukotriene receptor antagonists, 3) omalizumab (brand name XOLAIR), $RHHBY 4) dupilumab (brand name DUPIXENT) $SNY and $REGN https://www.barrons.com/articles/regeneron-blockbuster-dupixent-rival-ef230b36
0 · Reply
Gromit00
Gromit00 Sep. 8 at 4:45 PM
$LCTX Dear $RHHBY, Lineage just got a whole lot more expensive.
0 · Reply
Quantumup
Quantumup Sep. 8 at 10:25 AM
Citizens⬆️ $IDYA's PT to $45 from $41, reiterated at a Market Outperform and said, IDEAYA Biosciences's partner Hengrui showed strong numbers with DLL3-ADC IDE849 (SHR4849) in updated Ph1 data in Chinese patients that cleared the hurdle with more room than anticipated. $AZN $RHHBY $BMY $ZLAB ABBV Citizens added, IDE849 checked all the boxes and showed best-in-class efficacy as well as duration compared to the competitive landscape (details inside). We point to $IDYA's R&D day on Monday morning for more details and we expect the stock to react positively (+10%) on this strong update. We maintain our Market Outperform rating and increase our DCF-derived price target to $45 from $41 based on an increased probability of success (25% from 15%) for IDE849.
0 · Reply
Fingerlickengood
Fingerlickengood Sep. 7 at 6:54 PM
$CDXS $ALNY $RHHBY https://www.biotechtv.com/post/corsera-health-john-maraganore
3 · Reply
Fingerlickengood
Fingerlickengood Sep. 7 at 6:48 PM
$CDXS $ALNY $RHHBY This statement from the attached article stands out to me regarding Corsera Health, "With a preventive RNAi medicine expected to enter the clinic by the end of 2025, administered once-annually and priced to enable broad access, Corsera Health aims to prevent cumulative cardiovascular damage and support longer, healthier lives." This suggests they possibly have acquired something nearing or already FDA approved. What exactly is that is yet to be seen! https://www.streetinsider.com/dr/news.php?id=25280745
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Sep. 7 at 2:15 AM
$LMDX $RHHBY I get your frustration. A lot of us feel burned. The truth is, there’s a lot more to this story than just a ‘dead stock.’ Some of the most valuable assets — like the TB test and other pipeline IP — were never properly accounted for in the Roche deal. Insiders made out okay, but regular shareholders didn’t. You’re not wrong to feel scammed.
1 · Reply
DmcMouse
DmcMouse Sep. 5 at 8:38 PM
$LMDX what is everyone hearing anything good? Come one $RHHBY pay us our shares. Your gonna make enough take care of us little guys for once! Do the right thing.......$RHHBY
1 · Reply
Fingerlickengood
Fingerlickengood Sep. 5 at 5:03 PM
$CDXS $RHHBY $ALNY https://www.roche.com/media/releases/med-cor-2025-08-30
1 · Reply
ZacksResearch
ZacksResearch Sep. 5 at 3:52 PM
$RHHBY eyeing growth 👁️ New Vabysmo data shows extended dosing and vision gains, strengthening its case in eye disease treatment. See the full story here 👉 https://www.zacks.com/stock/news/2747619/rhhby-posts-positive-data-on-vabysmo-in-namd-at-euretina-congress?cid=sm-stocktwits-2-2747619-teaser-11140&ADID=SYND_STOCKTWITS_TWEET_2_2747619_TEASER_11140
0 · Reply
ZacksResearch
ZacksResearch Sep. 5 at 2:52 PM
$RHHBY’s Vabysmo shows strong promise in treating nAMD — a potential game-changer in eye care? 👀 📈 New data from AVONELLE-X and SALWEEN studies reinforce its efficacy, safety, and durability for nAMD. 💥 Nearly 80% of patients extended treatment intervals to 3-4 months with sustained vision stability. Find out why this could impact the nAMD treatment market here 👉 https://www.zacks.com/stock/news/2747619/rhhby-posts-positive-data-on-vabysmo-in-namd-at-euretina-congress?cid=sm-stocktwits-2-2747619-body-11139&ADID=SYND_STOCKTWITS_TWEET_2_2747619_BODY_11139
0 · Reply
samsha1
samsha1 Sep. 5 at 4:35 AM
$ABBV $RHHBY $SLS $XBI GPS target- • ~50–70% of MDS patients show detectable WT1 expression (by PCR or IHC). • Expression levels are typically lower than in AML, but they increase as MDS progresses to AML. • High WT1 levels in MDS are correlated with poor prognosis, higher blast counts, and shorter survival. 🔑 Clinical use: • WT1 is frequently monitored as a minimal residual disease (MRD) biomarker in MDS and AML. • Rising WT1 transcript levels in MDS patients can predict impending leukemic transformation.
2 · Reply
ImYourPhuckleberry
ImYourPhuckleberry Sep. 5 at 2:19 AM
$LMDX $RHHBY
0 · Reply
cb5000calls
cb5000calls Sep. 5 at 1:59 AM
$SLS ✅ Net impact: VERONA’s miss strengthens the case that SLS is holding two of the very few assets with true differentiation in myeloid disease. That naturally makes them more attractive to potential buyers, especially AbbVie/Roche (to backstop VEN) and any large oncology company wanting exposure to AML/MDS. $XBI $ABBV $RHHBY
0 · Reply
Quantumup
Quantumup Sep. 4 at 11:50 AM
Oppenheimer🏁 $BBOT at an Outperform rating and a $23 price target. $BBIO $RHHBY $LLY $MRK NVS RVMD ERAS VSTM Oppenheimer said: We are initiating on $BBOT with an Outperform rating and $23 price target. The company's motto "Best-in-RAS" succinctly summarizes our investment thesis: We think $BBOT is developing drugs that can unlock the full potential of targeting this pathway. The significance can't be understated: The RAS pathway is active in >50% of cancers—a Holy Grail for cancer therapy—but current drugs only work sparingly in some patients. $BBOT is out to change that, beginning with BBO-8520, a souped-up KRAZATI that targets the KRASG12C mutant. Some would argue that G12C is getting overly crowded, but to us the drug is just the opening act. In a future where combinations reign supreme, we think $BBOT has the building blocks to become the leader—with BBO-10203 its ace in the hole. $BBOT
0 · Reply
lmdxxxxxxxxxx
lmdxxxxxxxxxx Sep. 3 at 8:53 PM
$LMDX $RHHBY @BillGatesx #gates How’s our TB test investment doing?
0 · Reply
Quantumup
Quantumup Sep. 3 at 7:53 PM
Oppenheimer reiterated $OLMA Outperform-$22 and said that It Thinks a Bidding War is a Real Possibility if $RHHBY's PersevERA trial—Expected Any Day—Reads Out Positively. $PFE $NVS $RHHBY AZN LLY $XBI Oppenheimer said in its note: We had a chance to speak with Olema management after yesterday's announcement that Pfizer will test its next-generation CDK4-selective drug atirmociclib in a Phase 1b/2 combination trial with Olema's palazestrant. $OLMA shares have gained 15% (vs. $XBI 2%) since the news, so investors clearly aren't viewing this as typical run-of-the-mill research collaboration. To us, it is more strategic. Alongside the palazestrant + ribociclib combination (i.e., OPERA-02) with Novartis, Olema now has two of the big three players in HR-positive breast cancer with a seat at the data table-which under ideal circumstances may set the scene for a future bidding war. We think that's a real possibility if Roche's PersevERA trial—expected any day—reads out positively.
1 · Reply
scientificway
scientificway Sep. 3 at 3:30 PM
$RHHBY strong buy. PMN, Have cash and good result. Should be 0.5-9 very rare so oversold
0 · Reply
Cytomight
Cytomight Aug. 27 at 1:24 PM
$CYDY $MRK $RHHBY MUST READ ‼️THIS IS WHY CHECKPOINT INHIBITORS WILL OWN THE SOLID TUMOR MARKET ALONG SIDE LL‼️🫣🙌🏼
1 · Reply
scientificway
scientificway Aug. 26 at 7:00 PM
$RHHBY check out, XTNT Can not resist to buy
0 · Reply